Nasoflo Mechanism of Action

Pharmacology: Pharmacodynamics: Mechanism of Action: Fluticasone propionate is a topically active, synthetic, trifluorinated corticosteroid. It has a high affinity for glucocorticoid receptor with negligible activity at androsterone, progesterone, estrogen, or mineralocorticoid receptors.
It has anti-inflammatory and immunosuppressant activities after topical application to the nasal mucosa.
In patients with allergic rhinitis, the onset of symptomatic relief may occur within 12 to 48 hours after initiation of intranasal fluticasone propionate therapy in adults and within 36 hours in children; however, in most patients, up to 2 to 4 days are required for optimum effectiveness.
Pharmacokinetics: Fluticasone propionate is poorly absorbed from the respiratory and gastrointestinal tracts after nasal inhalation as an aqueous spray. The absolute systemic bioavailability of intranasal fluticasone propionate is less than 2%. Much of the intranasal dose of corticosteroids is swallowed and undergoes extensive first-pass metabolism in the liver.
Fluticasone propionate is approximately 91% bound to human plasma proteins.
Fluticasone propionate is rapidly metabolized in the liver by the cytochrome P-450 isoenzyme CYP3A4. The main metabolic product is the 17β-carboxylic acid derivative, which is produced by esterase-catalyzed hydrolysis and has no significant glucocorticoid or anti-inflammatory activity. This is then largely excreted in feces, with less than 5% being excreted in urine.